NCT07677982 Consent Understanding and Propofol Requirement During Endobronchial Ultrasound
| NCT ID | NCT07677982 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uludag University |
| Condition | ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION |
| Study Type | OBSERVATIONAL |
| Enrollment | 75 participants |
| Start Date | 2026-07-10 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 75 participants in total. It began in 2026-07-10 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn whether a participant's understanding of the informed consent information is related to the amount of propofol needed during endobronchial ultrasound (EBUS). EBUS is a procedure that uses a thin camera and ultrasound to look at lymph nodes and other areas inside the chest. Propofol is a sedative medicine used to help participants stay comfortable during the procedure. Before EBUS, all participants will receive the usual information about the procedure as part of routine care. After this routine consent process, participants will answer short questions about what they understood. They will also answer questions about their anxiety before the procedure. The study will not change the usual consent process, sedation plan, or medical care. During EBUS, participants will receive usual sedation and monitoring according to routine clinical practice. The research team will record how much sedative medicine is used, whether extra sedation is needed, whether any important clinical events occur, and how participants recover after sedation. The main question is whether participants who understand the consent information better need less propofol during EBUS.
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Scheduled for elective endobronchial ultrasound * ASA physical status I to III * Ability to read and understand Turkish * Provision of written informed consent for study participation Exclusion Criteria: * Active psychiatric disease that may affect the informed consent process, anxiety assessment, or communication * Cognitive impairment, including dementia or delirium * Contraindication or known allergy to propofol, midazolam, or remifentanil * Emergency EBUS procedure * Regular anxiolytic or sedative drug use within the last month * Illiteracy * Turkish language barrier * Advanced organ failure or decompensated systemic disease that may significantly affect sedative drug response, hemodynamic stability, communication, or consent assessment
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07677982 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ENDOBRONCHIAL ULTRASOUND - TRANSBRONCHIAL NEEDLE ASPIRATION. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07677982 currently recruiting?
Yes, NCT07677982 is actively recruiting participants. Contact the research team at gkizilkale@uludag.edu.tr for enrollment information.
Where is the NCT07677982 trial being conducted?
This trial is being conducted at Bursa, Turkey (Türkiye).
Who is sponsoring the NCT07677982 clinical trial?
NCT07677982 is sponsored by Uludag University. The trial plans to enroll 75 participants.